6 results about "Heparin-DHE" patented technology

The present invention provides an anticoagulant reversal agent which is a compound having the structure represented by formula I, a salt thereof, or a deuterated thereof. Experimental results have shown that the compound according to the present invention can more effectively suppress hemorrhagic complications caused by anticoagulants such as warfarin, heparin, and enoxaparin sodium, and exhibits high efficacy over a broad spectrum.

The invention discloses a cationic fluorescent probe with long wavelength emission as well as a preparation method and application of the cationic fluorescent probe. The fluorescent probe disclosed by the invention has the characteristic of emitting red fluorescence, the probe is combined with heparin through electrostatic interaction, and the fluorescence is quenched, so that the heparin is detected; furthermore, the protamine is specifically combined with the heparin, probe molecules are released, fluorescence is recovered, and the protamine is detected; the long-wavelength fluorescent probe provided by the invention has good selectivity and sensitivity on heparin and protamine, and can be applied to a serum dilution environment.

Disclosed herein are compositions and methods for treatment or prevention of a respiratory viral infection. A composition of the present disclosure comprises one or more of heparin, or N-acetylcysteine. A composition for treatment or prevention of a respiratory viral infection may be administered by inhalation in intervals. Administration of a composition may treat or prevent a viral infection.

The application relates to the technical field of heparin and protamine analysis, in particular to a heparin and protamine dose determination method. The method comprises the following steps: obtaining a first sample set A, wherein A i is the ith first sample, A i is obtained by adding different doses of a preset chemical substance in a blood sample of a target individual; obtaining a whole blood activated coagulation time detection result set B; obtaining a target model according to the whole blood activated coagulation time detection result in B, the dose of the corresponding added preset chemical substance and a preset model; and obtaining the dose of the preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual according to the target whole blood activated coagulation time and the target model. The application can determine the heparin dose and the protamine dose suitable for the target individual and corresponding to the target whole blood activated coagulation time, and provides a reference for the heparin dose and the protamine dose in an actual application scene.

The invention discloses preparation and application of an anti-fouling, anti-coagulation and thrombolysis multifunctional zwitterionic hydrogel composite coating. The composite coating is composed of a mediating layer, a zwitterionic polymer hydrogel coating, heparin and urokinase. The multifunctional composite anticoagulant coating is formed through efficient combination of anti-fouling and biological inert anticoagulation of zwitterionic polymer hydrogel, biological active anticoagulation of heparin and thrombolysis of fibrinolytic factors such as urokinase. According to the method for preparing the composite coating by constructing the zwitterionic polymer hydrogel coating, regulating and controlling the number of amino groups and carboxyl groups on the surface, grafting heparin at a tip point and then fixing urokinase at a single point, biological inertia and biological activity synergistic anticoagulation and seamless connection of passive defense anticoagulation and efficient active attack thrombolysis are better realized. The method is suitable for directly constructing coatings on the surfaces of devices of different materials, shapes and sizes, and a new way is provided for long-term efficient antithrombotic modification of the surfaces of instruments needing long-term implantation.

Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.